Waters Corp.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US9418481035
USD
396.37
-1.25 (-0.31%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Waters Corp. stock-summary
stock-summary
Waters Corp.
Pharmaceuticals & Biotechnology
Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans. It also designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA product line. It is also a developer and supplier of software-based products that interface with the Company's instruments, as well as other suppliers' instruments. Its LC and LC-MS instruments are utilized in a range of industries to detect, identify, monitor and measure the chemical, physical and biological composition of materials, and to purify a range of compounds.
Company Coordinates stock-summary
Company Details
34 MAPLE ST , MILFORD MA : 01757-3604
stock-summary
Tel: 1 508 47820001 508 4823448
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 129 Schemes (39.48%)

Foreign Institutions

Held by 374 Foreign Institutions (38.99%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Christopher O'Connell
Chairman of the Board
Dr. Udit Batra
President, Chief Executive Officer, Director
Mr. Thomas Salice
Lead Independent Director
Ms. Linda Baddour
Independent Director
Dr. Michael Berendt
Independent Director
Mr. Edward Conard
Independent Director
Mr. Gary Hendrickson
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
771 Million
(Quarterly Results - Jun 2025)
Net Profit:
147 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 49,633 Million (Mid Cap)

stock-summary
P/E

85.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.52

stock-summary
Return on Equity

30.68%

stock-summary
Price to Book

22.98